Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Other Operating Expenses (2016 - 2025)

Bioadaptives' Other Operating Expenses history spans 7 years, with the latest figure at $27438.0 for Q4 2025.

  • On a quarterly basis, Other Operating Expenses fell 65.14% to $27438.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $234162.0, a 13.53% decrease, with the full-year FY2025 number at $234162.0, down 13.53% from a year prior.
  • Other Operating Expenses hit $27438.0 in Q4 2025 for Bioadaptives, up from $18569.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for BDPT hit a ceiling of $207758.0 in Q1 2021 and a floor of $8919.0 in Q1 2023.
  • Historically, Other Operating Expenses has averaged $59803.2 across 5 years, with a median of $60545.0 in 2022.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 662.84% in 2021 and later crashed 87.44% in 2023.
  • Tracing BDPT's Other Operating Expenses over 5 years: stood at $63384.0 in 2021, then tumbled by 82.79% to $10911.0 in 2022, then skyrocketed by 113.21% to $23263.0 in 2023, then skyrocketed by 238.38% to $78718.0 in 2024, then crashed by 65.14% to $27438.0 in 2025.
  • Business Quant data shows Other Operating Expenses for BDPT at $27438.0 in Q4 2025, $18569.0 in Q3 2025, and $82390.0 in Q2 2025.